Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 7/20 | 0.37 |
| ▸ | RORC | P51449 | 9/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | BCR | P11274 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18555119 | 0.99 | CFD (0.37) | CFDRORCCTSCABL1BCR | |
| Hydrochloric Acid SCHEMBL29545105 | 0.99 | CFD (0.37) | CFDRORCCTSCABL1BCR | |
| SCHEMBL17024751 | 0.90 | CFD (0.38) | CFDCTSCABL1BCR | |
| SCHEMBL18555502 | 0.86 | CFD (0.42) | CFDCTSC | |
| SCHEMBL29545547 | 0.86 | CFD (0.42) | CFDCTSC | |
| SCHEMBL17023724 | 0.86 | CFD (0.42) | CFDCTSC | |
| SCHEMBL17053073 | 0.86 | CFD (0.42) | CFDCTSC | |
| SCHEMBL18576565 | 0.86 | CFD (0.42) | CFDCTSC | |
| SCHEMBL17031918 | 0.85 | CTSC (0.36) | CFDCTSC | |
| SCHEMBL20378093 | 0.85 | CFD (0.37) | CFDCTSCABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10092584-B2 | Compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3340982-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035408-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CFD 1/4885RORC 3261/4885CTSC 473/4885 |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | CFD 1/4885RORC 3261/4885CTSC 473/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CFD 1/4885RORC 3181/4885CTSC 464/4885 |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CFD 1/4885RORC 3261/4885CTSC 473/4885 |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885RORC 2805/4885CTSC 844/4885 |
| US-10092584-B2 | Compounds for the treatment of medical disorders | CFD, TFPI, CFH | CFD 1/4885RORC 4670/4885CTSC 395/4885 |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CFD 1/4885RORC 3261/4885CTSC 473/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885RORC 2805/4885CTSC 844/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CFD 1/4885RORC 3261/4885CTSC 473/4885 |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | CFD 1/4885RORC 4670/4885CTSC 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.